Specifically, human monoclonal antibodies against IL-1β (canakinumab) have shown clinical benefit in patients with NLRP3-related disorders, while clinical trials for use in autoimmune disorders are already underway25. The gene discussed is IL1B; the disease is Autoimmunity.